Agilent (AG8) Stock Price & Analysis
AG8 Stock Chart & Stats
- Day’s Range
- EUR 156.45 - EUR 163.25
- 52-Week Range
- EUR 94.18 - EUR 164.80
- Previous Close
- EUR 162.90
- Volume
- 0
- Average Volume (3M)
- 37
- Market Cap
- EUR 44.00B
- Enterprise Value
- EUR 41.35B
- Total Cash (Recent Filing)
- EUR 1.76B
- Total Debt (Recent Filing)
- EUR 3.95B
- Price to Earnings (P/E)
- 34.4
- Beta
- 0.56
- Next Earnings
- Nov 23, 2026 (Est.)
- EPS Estimate
- 1.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.58%
Bulls Say, Bears Say
Bulls Say
Raised Growth Outlook
The raised FY26 outlook indicates improving demand and management confidence across Agilent’s portfolio. Higher expected revenue and earnings growth can support investment in innovation, strengthen operating leverage, and provide a durable foundation for performance over the next several quarters.
Recurring Revenue Model
Agilent’s installed-base model creates repeat demand for consumables, maintenance, software, and support after instruments are placed. This recurring revenue mix can improve customer retention, increase lifetime value, and make the business more resilient than a model dependent only on new equipment sales.
Strong Cash Generation
Robust free cash flow demonstrates that Agilent converts substantial accounting earnings into financial resources. That cash supports dividends, repurchases, research, and balance-sheet management, while providing flexibility to sustain investment and absorb moderate changes in customer spending.
Bears Say
Gross-margin Compression
The sharp decline in gross margin raises questions about the durability of Agilent’s historical profitability profile. If mix, pricing, or cost pressures persist, lower gross profit per dollar of revenue could constrain operating leverage, reduce earnings upside, and limit flexibility for continued investment.
Higher Debt Burden
Rising debt reduces financial flexibility even though current leverage remains moderate. A larger debt balance can increase interest and refinancing exposure, leave fewer resources for acquisitions or shareholder returns, and make Agilent less able to respond aggressively if operating conditions weaken.
Cash Conversion Variability
Operating cash flow below accounting earnings suggests working-capital or timing effects are limiting cash realization in some periods. Persistent conversion variability could make internal funding less predictable, create quarter-to-quarter volatility, and weaken the reliability of cash available for investment or capital returns.
Agilent News
AG8 FAQ
What was Agilent’s price range in the past 12 months?
What is Agilent’s market cap?
When is Agilent’s upcoming earnings report date?
How were Agilent’s earnings last quarter?
Is Agilent overvalued?
Does Agilent pay dividends?
What is Agilent’s EPS estimate?
How many shares outstanding does Agilent have?
What happened to Agilent’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Agilent?
What is the TipRanks Smart Score and how is it calculated?
Agilent Stock Smart Score
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell
- Employees
- 18,200
- Website
- www.agilent.com
- Address
- 5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, US
Agilent (AG8) Earnings & Revenues
AG8 Company Deck
AG8 Earnings Call
Earnings Call SentimentPositive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.
View all DE:AG8 earnings summariesAG8 Net sales Breakdown
- 39.23% Life Sciences and Diagnostics Markets
- 41.85% Agilent CrossLab
- 18.91% Applied Markets
AG8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 6 | 4 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 8 | 0 | 4 |